We cherish the love of a quality job performed and the satisfaction of a partner, be it a customer, a collaborator or a team mate. We are moved by challenges, innovation and creativity, and above all, we put values of trust, reliability and professionalism in all actions we undertake. |
Who We Are
B2G Life Sciences capitalizes on the expertise of long-international-experienced executives and staff, in the fields of clinical research and development & medical affairs, as well as medical communication for health products.
We are an innovative consulting & CRO, dedicated to the pharmaceutical and biotechnology industry.
We believe in the opportunity of shortening the distance between the industry's projects and markets' unmet medical needs.
Through our presence both in Paris and in Tunis, we endeavor to build bridges and gateways between operators in different regional markets.
We are an innovative consulting & CRO, dedicated to the pharmaceutical and biotechnology industry.
We believe in the opportunity of shortening the distance between the industry's projects and markets' unmet medical needs.
Through our presence both in Paris and in Tunis, we endeavor to build bridges and gateways between operators in different regional markets.
Our Vision
We believe in the opportunity of shortening the distance
between the industry's projects and markets' unmet medical needs.
New Opportunities
While often rare and orphan, genetic diseases are among the most explored fields in Medicine by small or medium size organizations. This is due to several reasons:
It is a niche market where competition from large pharmaceutical laboratories remains relatively low;
These diseases perfectly fit in the highly skilled field of expertise that constitutes the basis to the founding of these organizations;
These entities tend to take advantage of regulations in Europe and the USA for the development of orphan drugs.
It is a niche market where competition from large pharmaceutical laboratories remains relatively low;
These diseases perfectly fit in the highly skilled field of expertise that constitutes the basis to the founding of these organizations;
These entities tend to take advantage of regulations in Europe and the USA for the development of orphan drugs.